Association of sentinel lymph node biopsy with survival for head and neck melanoma: Survival analysis using the SEER database

JAMA Otolaryngology - Head and Neck Surgery

Volumn 140, Issue 12, 2014, Pages 1101-1109

  Sperry, Steven M ^a   Charlton, Mary E ^b   Pagedar, Nitin A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; NECK DISSECTION; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; UNITED STATES; VERY ELDERLY; EPIDEMIOLOGY; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MELANOMA; MIDDLE AGED; NECK DISSECTION; RETROSPECTIVE STUDIES; SEER PROGRAM; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 84919776937     PISSN: 21686181     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaoto.2014.2530     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. doi:10.3322/caac.20073.
2. Pollack LA, Li J, Berkowitz Z, et al. Melanoma survival in the United States, 1992 to 2005. J Am Acad Dermatol. 2011;65(5)(suppl 1):S78-S86, e10.
3. Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206. doi:10.1200/JCO.2009.23.4799.
4. Morton DL,Wen DR,Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4): 392-399.
5. Gershenwald JE, ThompsonW, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17(3):976-983.
6. Morton DL, Hoon DSB, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg. 2003;238(4): 538-549. doi:10.1097/01.sla.0000086543.45557.cb.
7. Gutzmer R, Al Ghazal M, Geerlings H, Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol. 2005;153(6):1137-1141. doi:10.1111/j .1365-2133.2005.06941.x.
8. Medalie NS, Ackerman AB. Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: an assertion based on comprehensive, critical analysis: part I. Am J Dermatopathol. 2003;25(5): 399-417.
9. McMasters KM. What good is sentinel lymph node biopsy for melanoma if it does not improve survival? Ann Surg Oncol. 2004;11(9):810-812. doi: 10.1245/ASO.2004.07.919.
10. Freeman SR, Gibbs BB, Brodland DG, Zitelli JA. Prognostic value of sentinel lymph node biopsy compared with that of Breslow thickness: implications for informed consent in patients with invasive melanoma. Dermatol Surg. 2013;39(12): 1800-1812. doi:10.1111/dsu.12351.
11. Morton DL, Thompson JF, Cochran AJ, et al MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599-609. doi:10.1056/NEJMoa1310460.
12. Morton DL, Thompson JF, Cochran AJ, et al MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355 (13):1307-1317. doi:10.1056/NEJMoa060992.
13. Gimotty PA, Yoon F, Hammond R, Rosenbaum P, Guerry D. Therapeutic effect of sentinel lymph node biopsy in melanoma remains an open question. J Clin Oncol. 2009;27(26):4236-4238. doi:10.1200/JCO.2009.23.4518.
14. Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol. 2008;144(4):515-521. doi:10.1001/archderm.144.4.515.
15. Fadaki N, Li R, Parrett B, et al. Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome? Ann Surg Oncol. 2013; 20(9):3089-3097. doi:10.1245/s10434-013-2977-7.
16. Ghazal Al P, Gutzmer R, Satzger I, et al. Lower prevalence of lymphatic metastasis and poorer survival of the sentinel node-negative patients limit the prognostic value of sentinel node biopsy for head or neck melanomas. Melanoma Res. 2014;24 (2):158-164.
17. McMasters KM, Noyes RD, Reintgen DS, et al Sunbelt Melanoma Trial. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86(4): 212-223. doi:10.1002/jso.20084.
18. Saltman BE, Ganly I, Patel SG, et al. Prognostic implication of sentinel lymph node biopsy in cutaneous head and neck melanoma. Head Neck. 2010;32(12):1686-1692. doi:10.1002/hed.21390.
19. NCCN Clinical Practice Guidelines in Oncology: Melanoma. National Comprehensive Cancer Network website. http://www.nccn.org. Accessed October 29, 2013.
20. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26(4):734-753. doi:10.1002/sim.2580.
21. Cormier JN, Xing Y, Ding M, et al. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005;23(25):6054-6062. doi:10.1200/JCO.2005.21.360.
22. Stitzenberg KB, Thomas NE, Beskow LM, Ollila DW. Population-based analysis of lymphatic mapping and sentinel lymphadenectomy utilization for intermediate thickness melanoma. J Surg Oncol. 2006;93(2):100-107. doi:10.1002/jso.20403.
23. Sondak VK, Taylor JMG, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11(3):247-258. doi:10.1245/ASO.2004.03.044.
24. Balch CM, Soong S-J, Gershenwald JE, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20(12):3961-3968. doi:10.1245/s10434-013-3100-9.
25. Chao C, Martin RCG II, Ross MI, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol. 2004; 11(3):259-264. doi:10.1245/ASO.2004.04.015.
26. Kemeny MM, Busch E, Stewart AK, Menck HR. Superior survival of young women with malignant melanoma. Am J Surg. 1998;175(6):437-444.
27. Stidham KR, Johnson JL, Seigler HF. Survival superiority of females with melanoma: a multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg. 1994;129(3):316-324.
28. MacKie RM, Hole D, Hunter JA, et al Scottish Melanoma Group. Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94. BMJ. 1997;315(7116):1117-1121.
29. O'Brien CJ, Coates AS, Petersen-Schaefer K, et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg. 1991;162(4):310-314.
30. Golger A, Young DS, Ghazarian D, Neligan PC. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study. Arch Otolaryngol Head Neck Surg. 2007;133(5):442-447. doi:10.1001 /archotol.133.5.442.
31. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622-3634.
32. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399-424. doi:10.1080/00273171.2011.568786.
33. Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25(1):1-21. doi:10.1214/09-STS313.
34. Hansen BB, Bowers J. Covariate balance in simple, stratified and clustered comparative studies. Stat Sci. 2008;23(2):219-236. doi:10.1214/08-STS254.
35. Iacus SM, King G, Porro G. Causal inference without balance checking: coarsened exact matching. Polit Anal. 2012;20(1):1-24. doi:10.1093/pan/mpr013.
36. Thoemmes F. Propensity score matching in SPSS. arXiv. http://arxiv.org/abs/1201.6385. Accessed November 4, 2013.
37. Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1-28.
38. Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007;15(3):199-236. doi:10.1093/pan/mpl013.
39. Hansen BB. Full matching in an observational study of coaching for the SAT. J Am Stat Assoc. 2004;99(467):609-618. doi:10.1198/016214504000000647.
40. Love TE. Spreadsheet-based sensitivity analysis calculations for matched samples. Center for Health Care Research & Policy, CaseWestern Reserve University, 2008. http://www.chrp.org/propensity. Accessed December 31, 2013.
41. Satzger I, Meier A, Hoy L, et al. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. Ann Surg Oncol. 2011;18(2):514-520. doi: 10.1245/s10434-010-1318-3.
42. Austin PC. A tutorial on the use of propensity scoremethods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments [published online September 30, 2013]. Stat Med. doi:10.1002 /sim.5984.
43. Peabody JW, Luck J, Jain S, Bertenthal D, Glassman P. Assessing the accuracy of administrative data in health information systems. Med Care. 2004;42(11):1066-1072.
44. Nathan H, Pawlik TM. Limitations of claims and registry data in surgical oncology research. Ann Surg Oncol. 2008;15(2):415-423. doi:10.1245 /s10434-007-9658-3.